Stockscreener 앱 받기
0.9689
5.93%
-0.0611
시간 외 거래:
.99
0.0211
+2.18%
전일 마감가:
$1.03
열려 있는:
$1.02
하루 거래량:
13.76M
Relative Volume:
1.76
시가총액:
$261.25M
수익:
$2.02M
순이익/손실:
$-97.59M
주가수익비율:
-1.6859
EPS:
-0.5747
순현금흐름:
$-102.38M
1주 성능:
-27.69%
1개월 성능:
+4.17%
6개월 성능:
-9.45%
1년 성능:
-58.42%
1일 변동 폭
$0.939
$1.06
1주일 범위
$0.939
$1.11
52주 변동 폭
$0.5469
$2.82
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.9689 | 288.51M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing - MSN
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results - grafa.com
Humacyte stock rises on positive dialysis trial results By Investing.com - Investing.com India
Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure - Stock Titan
Humacyte’s bioengineered vessel shows benefit for women on dialysis - Investing.com UK
Humacyte’s bioengineered vessel shows benefit for women on dialysis By Investing.com - Investing.com Canada
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting - The Manila Times
Bioengineered blood vessel helps women on dialysis avoid catheters longer - Stock Titan
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses - MSN
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Director at Humacyte (NASDAQ: HUMA) receives 80,000 stock options grant - Stock Titan
Humacyte (HUMA) director receives 80,000 stock options at $1.08 exercise price - Stock Titan
Humacyte (HUMA) director receives 80,000 stock options at $1.08 strike price - Stock Titan
Humacyte (HUMA) CEO indirectly awarded 80,000 stock options via spouse - Stock Titan
[Form 4] Humacyte, Inc. Insider Trading Activity - Stock Titan
Humacyte (HUMA) director Keith Anthony Jones awarded 80,000 stock options at $1.08 - Stock Titan
Humacyte (HUMA) director receives grant of 80,000 stock options at $1.08 strike - Stock Titan
Director at Humacyte (NASDAQ: HUMA) granted 80,000 stock options - Stock Titan
Director at Humacyte (HUMA) receives grant of 80,000 stock options - Stock Titan
Humacyte (HUMA) director Emery N. Brown receives 80,000 stock options award - Stock Titan
H.C. Wainwright raises Humacyte stock price target on trial data - Investing.com UK
Humacyte prices $50M public offering of common stock at $1.05/share - MSN
H.C. Wainwright raises Humacyte stock price target on trial data By Investing.com - Investing.com Australia
Humacyte Announces Proposed Public Offering to Fund Commercialization of Symvess and Pipeline Development - Minichart
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
HUMA Maintained by HC Wainwright & Co. -- Price Target Raised to $4.00 - GuruFocus
Humacyte Announces Underwritten Public Equity Offering to Fund Growth - TipRanks
Humacyte Enters Underwriting Agreement for 47.6M-Share Offering at $1.05, Nets ~$46.8M - TradingView
Humacyte (HUMA) prices 47.6M-share stock sale at $1.05 to fund Symvess - Stock Titan
Humacyte (NASDAQ: HUMA) priced 47.6M shares at $1.05; Phase 3 met endpoint - Stock Titan
Why Is Humacyte Stock Falling Thursday? - Benzinga
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $4 - Moomoo
Humacyte stock falls despite positive Phase 3 data - scanx.trade
Biggest stock movers: ORCL, HUMA, and more - Seeking Alpha
Humacyte (HUMA) Phase 3 trial meets dialysis access endpoint - grafa.com
Humacyte, Inc. Announces Underwritten Public Offering of Common Stock - Quiver Quantitative
Biotech Humacyte prices $50M sale to fund Symvess, dialysis filing - Stock Titan
Humacyte prices $50 million public offering at $1.05 per share By Investing.com - Investing.com South Africa
Humacyte prices $50 million public offering at $1.05 per share - Investing.com
Humacyte stock falls 6% on public offering announcement - Investing.com
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - Benzinga
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - Yahoo Finance
Humacyte, Inc. Announces Proposed Public Offering of Common Stock - Yahoo Finance
HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses - Stocktwits
Humacyte reports positive Phase 3 trial results for dialysis access By Investing.com - Investing.com South Africa
Humacyte Announces Positive Phase 3 Dialysis Access Results - TipRanks
Stocks to Watch : Oracle, Oxford Industries, Humacyte, PureCycle Technologies - marketscreener.com
Humacyte launches public offering of common stock By Investing.com - Investing.com South Africa
Humacyte reports positive Phase 3 trial results for dialysis access - Investing.com
Humacyte launches public offering of common stock - Investing.com
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Humacyte Inc 주식 (HUMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Constantino Michael T. | Director |
May 18 '26 |
Buy |
0.89 |
11,000 |
9,840 |
43,950 |
| Sander Dale A. | CFO and Chief Corp. Dev. Off |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
267,213 |
| Parikh Shamik J | Chief Medical Officer |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
272,713 |
2.60%
0.94%
자본화:
|
볼륨(24시간):